As part of the Nathan Schnaper Intern Program in Translational Cancer Research at the University of Maryland, Baltimore, Benick Mbaya studied how exercise can improve symptoms for women undergoing chemotherapy for breast cancer.

Sepsis kills 1 in 5 people worldwide. Dr. Ryan Pearson is developing nanoparticle-based therapies that could save thousands of lives every year.#BreakthroughsCantWaitUMB #SepsisResearch #Nanomedicine #UMBresearch

On October 24, 2025 the Physician Assistant Leadership and Learning Academy (PALLA) hosted an event titled Bridging the Gap: PAs Advancing Access in a Changing Healthcare Landscape at the University of Maryland, Baltimore.

Dr. Ryan Pearson explains how nanoparticles—tiny blebs engineered to shape immune responses—could revolutionize the way we treat inflammation and sepsis. #BreakthroughsCantWaitUMB #Nanomedicine #SepsisResearch #UMBresearch

University of Maryland, Baltimore President Bruce E. Jarrell, MD, FACS, speaks with University of Maryland VP for Research Patrick O'Shea, PhD, MS, and Robert K. Ernst, PhD, about the current state and future of research at the University of Maryland on this edition of Virtual Face to Face. The program includes a wide ranging discussion and questions and comments from the live audience.

Dr. Ryan Pearson from the University of Maryland School of Pharmacy is using nanoparticles to fight sepsis, one of the deadliest medical emergencies. #BreakthroughsCantWaitUMB #SepsisResearch #Nanomedicine #UMBresearch

UMB President Bruce Jarrell, UMB deans, administrators, and vice presidents served lunch in appreciation of our dedicated staff during this annual Founders Week tradition.

University of Maryland, Baltimore had the opportunity to get a free lunch from President Bruce E. Jarrell, MD, FACS, deans and vice presidents in this annual Founders Week tradition.

Ryan Pearson, PhD, associate professor of pharmaceutical sciences and director of the Bio- and Nano-Technology Center at the University of Maryland School of Pharmacy has been awarded a $3.4 million grant from the National Institutes of Health to move forward with a unique approach to defeating sepsis using nanoparticles. His approach is different because the custom-designed nanoparticles are not used to transport other drugs, but are themselves the treatment.

As an ACS-IMPACT Research Scholar at the University of Maryland, Baltimore, Gabrielle Olibris spent her summer in the lab of Aditi Banerjee, PhD, targeting medulloblastoma, a pediatric brain cancer, with a novel therapeutic compound called BNPP-433.3 Beta.BNPP-433.3 Beta shows strong potential, she said, explaining, “This is already patented, so it’s a drug that’s already being used to treat prostate cancer.”By exploring a new use for an existing cancer drug, Olibris hopes to help advance research that could lead to safer, more effective treatments for children.#breakthroughscantwaitumb #cancerresearch